These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 26175400)

  • 61. From prevention to cure, repurposing anti-viral vaccines for cancer immunotherapy.
    Mamai O; Dodagatta-Marri E; Akhurst RJ
    Biotarget; 2018 Dec; 2():. PubMed ID: 30906919
    [No Abstract]   [Full Text] [Related]  

  • 62. Preventing cancer: the only way forward.
    Sarfati D; Gurney J
    Lancet; 2022 Aug; 400(10352):540-541. PubMed ID: 35988552
    [No Abstract]   [Full Text] [Related]  

  • 63. Analysis of a cancer dormancy model and control of immuno-therapy.
    Sheller B; D'Alessandro D
    Math Biosci Eng; 2015 Oct; 12(5):1037-53. PubMed ID: 26280178
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cancer immunotherapy: harnessing the immune system to battle cancer.
    Yang Y
    J Clin Invest; 2015 Sep; 125(9):3335-7. PubMed ID: 26325031
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The Adaptation Model of Immunity: Signal IV Matters Most in Determining the Functional Outcomes of Immune Responses.
    Manjili MH
    J Immunol; 2023 Mar; 210(5):521-530. PubMed ID: 36881868
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cellular stress responses and metabolic reprogramming in cancer progression and dormancy.
    Payne KK
    Semin Cancer Biol; 2022 Jan; 78():45-48. PubMed ID: 34098105
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cancer immunoediting and resistance to T cell-based immunotherapy.
    O'Donnell JS; Teng MWL; Smyth MJ
    Nat Rev Clin Oncol; 2019 Mar; 16(3):151-167. PubMed ID: 30523282
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunotherapy of cancer: targeting cancer during active disease or during dormancy?
    Shah SA; Zarei M; Manjili SH; Guruli G; Wang XY; Manjili MH
    Immunotherapy; 2017 Sep; 9(11):943-949. PubMed ID: 29338608
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The inherent premise of immunotherapy for cancer dormancy.
    Manjili MH
    Cancer Res; 2014 Dec; 74(23):6745-9. PubMed ID: 25411346
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Veterinary Oncology Immunotherapies.
    Bergman PJ
    Vet Clin North Am Small Anim Pract; 2018 Mar; 48(2):257-277. PubMed ID: 29224713
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cellular immunotherapy in ovarian cancer: Targeting the stem of recurrence.
    Wefers C; Lambert LJ; Torensma R; Hato SV
    Gynecol Oncol; 2015 May; 137(2):335-42. PubMed ID: 25727651
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prospects in cancer immunotherapy: treating advanced stage disease or preventing tumor recurrence?
    Manjili MH; Payne KK
    Discov Med; 2015 Jun; 19(107):427-31. PubMed ID: 26175400
    [TBL] [Abstract][Full Text] [Related]  

  • 73.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 4.